Retinoic acid (RA) is a master epigenetic regulator that plays a pivotal role in both breast morphogenesis and development. Here, we show for the first time that RA, via the RA receptor A (RARA), epigenetically regulates in a concerted fashion the transcription of two RA-responsive genes, the RA receptor B2 (RARb2) and the cellular retinol-binding protein 1 (CRBP1). Specifically, an impaired RA signal through RARA in human breast epithelial cells triggers a repressive epigenetic domino effect, involving first RARb2 and second CRBP1. The phenotype acquired by breast epithelial cells clearly implies that the resistance to RA-mediated growth inhibition precedes the acquisition of morphological epithelial transformation, thus supporting the occurrence of sequential transcriptional silencing of first RARb2 and second CRBP1. The identification of this epigenetic network mechanistically linking RARb2 and CRBP1 transcription provides the basis for devising more accurate epigenetic tests for the prediction of breast cancer risk.
Introduction
Retinoic acid (RA), the bioactive derivative of vitamin A or retinol, is a master epigenetic regulator of gene transcription (1) , which plays a pivotal role in postpuberty mammary gland morphogenesis and development (2, 3) . Once integrated through the RA receptor a (RARa), RA signal elicits chromatin modifications that enable transcription of the RA receptor h2 (RARb2; refs. 1, 4). RARh2 would then sustain its own transcription (5-7) and the transcription of a few downstream RA-responsive target genes.
By stably impairing the integration of RA signal through RARa in RA-sensitive breast cancer cells, we found recently that RARb2 falls into an aberrant transcriptional inactive status, which is marked by a critical level of repressive chromatin modifications, including, but not limited to, DNA hypermethylation (8) . Concomitant with the conversion of RARb2 alleles from a permissive transcriptional status into a nonpermissive status, cells are converted to RA resistance (8) . These findings led us to originally speculate that the propensity to RARb2 epigenetic silencing and RA resistance could be consequent to an altered retinol/RA metabolism, capable of creating an aberrant RA signal through RARa (8, 9) . Indeed, several proteins involved in either retinol or RA metabolism/transport can be found deranged or down-regulated in breast cancer cells (10) (11) (12) (13) . One of these proteins is the cellular retinol-binding protein 1 (CRBP1). In this study, we set out to test whether silencing CRBP1 in RA-sensitive cells could mechanistically lead to RARb2 silencing and RA resistance. Because CRBP1, in addition of being a retinol transport protein, is also involved in the maintenance of apicobasal-differentiated morphology of human breast epithelial cells (14) , we chose to knock down CRBP1 by RNA interference (RNAi) in nontransformed human breast epithelial cells (HME1). However, contrary to our hypothesis, we found that CRBP1 knockdown does not induce RARb2 silencing and RA resistance. We found instead that CRBP1 is a downstream RAR-regulated gene, consistent with reports pointing at CRBP1 like one of the few RAR targets (15) (16) (17) (18) (19) . First, we identified in the human CRBP1 a RA-responsive element (RARE), which is evolutionary conserved (15, 16) . Second, we found that both RARa and RARh2 can bind the human CRBP1-RARE region. Finally, when we impaired the integration of RA through either RARh2 or RARa in HME1 cells, we observed the conversion of CRBP1 alleles permissive for transcription into alleles nonpermissive for transcription. A fraction of nonpermissive alleles showed aberrant DNA hypermethylation. Apparently, an impaired integration of RA signal through RARa leads to a repressive epigenetic ''domino effect, '' involving first RARb2 and second CRBP1. The phenotypic analysis of HME1 clones, showing that the resistance to RA-mediated growth inhibition precedes the acquisition of morphologic phenotypes of epithelial transformation, further supported the occurrence of sequential transcriptional silencing of first RARb2 and second CRBP1.
Materials and Methods
Cells and cell cultures. The human telomerase-immortalized nontransformed breast epithelial cell strain HME1 (Clontech, Mountain View, CA) was grown in mammary epithelial growth medium (MEGM) plus bovine pituitary extract (Cambrex, Walkersville, MD) as per manufacturer's instructions. The monkey kidney COS cell line and the human breast cancer MDA-MB-231 cell line (American Type Culture Collection, Manassas, VA) were grown in DMEM plus 5% fetal bovine serum (Invitrogen, Carlsbad, CA).
HME1 cells and derived clones were grown on reconstituted basement membrane in three-dimensional cultures to induce breast epithelial differentiation into acini-like structures essentially as described (20) . Briefly, single cells were induced to form acini on chamber slides coated with Matrigel (BD Biosciences, San Jose, CA) in medium plus 2% Matrigel for 10 to 15 days. After fixation with 4% paraformaldehyde, the Golgi apparatus was stained with anti-GM 130 antibody (Ab) (1:400; BD Biosciences) followed by goat anti-mouse Alexa Fluor 546 Ab (1:500; Molecular Probes, Eugene, OR). Integrin was stained with anti-CD49f Ab (1:200; Chemicon, Temecula, CA) followed by anti-rat Alexa Fluor 488 Ab (1:400; Molecular Probes). Nuclei were counterstained with 300 nM 4 ¶,6-diamidino-2-phenylindole (Sigma, St. Louis, MO). At least 30 acini per each clone were analyzed by confocal microscopy (SP2 spectral confocal microscope, Leica, Microsystem, Wetzlar, DE) to inspect for the presence of a hollow lumen and apicobasal polarization. The phenotype observed in 70% or more of the acini was considered to be the prevalent phenotype.
For the colony formation assay, exponentially growing cells were seeded at 3 Â 10 2 per well in six-well plates and allowed to attach for 48 hours. After treatment with either 0.1 AM RA or vehicle (ethanol) for 24 hours, the medium was replaced with drug-free medium and cells were allowed to grow for 10 to 14 days, until the appearance of colonies was observed. Colonies were then fixed with methanol, stained with Giemsa, and scored to establish the colony formation index.
For the anchorage-independent colony formation assay, 1 Â 10 4 cells per well resuspended in semisolid medium containing 0.3% agarose were layered on 0.5% agarose in six-well plates and cultured for 4 weeks. Foci were counted in 10 random fields per each triplicate sample under a Nikon (Melville, NY) Eclipse E600 microscope. Each experiment was repeated three times.
Drugs. RA and 5-aza-2 ¶-deoxycytidine (5-Aza; Sigma) were dissolved in 100% ethanol and 0.45% NaCl containing 10 nM sodium phosphate (pH 6.8), respectively, and stored in aliquots at À80jC in the dark.
RNAi. Short hairpin RNA (shRNA) sequences targeting CRBP1, RARb2, and RARa mRNAs were cloned into the pSUPER-retro vector (Oligoengine, Seattle, WA). The sequences targeted by RNAi were as follows: CRBP1-A, 5 ¶-GTGCATGACAACAGTGAGC-3 ¶; CRBP1-B, 5 ¶-GGTGTGGTCTGCAAGCAAG-3 ¶ (Genbank NM_002899, nucleotides 371-389 and 495-513, respectively); RARb2-A , 5 ¶-GCTGGCTTGTCTGTCATAA-3 ¶; RARb2-B , 5 ¶-GGGGCA-GAGTTTGATGGAG-3 ¶ (Genbank NM_000965.2, nucleotides 303-321 and 371-389, respectively); and RARa-B (8), 5 ¶-AGCGCACCAGGAAACCTTC-3 ¶ (Genbank NM_000964, nucleotides 681-699). The control mock sequence 5 ¶-ACGTACGTACGTAGTGGGG-3 ¶, which should not recognize any human mRNA, was cloned in the pSUPER-retro vector and used as a control. The silencing effect of each of these sequences was tested by transient cotransfection with the cognate exogenous cDNAs in COS cells. The cDNA sequences included the following: (a) the RARa1 cDNA cloned into pSG5 plasmid (kindly provided by Dr. Fausto Andreola, NCI, Bethesda, MD); (b) the CRBP1 cDNA cloned from MDA-MB-468 cell line in frame with the TAG sequence present into the pCMV-TAG vector (Stratagene, La Jolla, CA) after PCR amplification using the primers 5 ¶-TATGGAATTCCTGGCTCCAGT-CACTCCCGAA-3 ¶ (sense) and 5 ¶-TATCTCGAGCTGATTGGTTGGGA-CAAGGTTGTCT-3 ¶ (antisense) containing restriction sites for EcoRI and XhoI, respectively; and (c) the RARb2 cDNA cloned from T47D into pCDNA3.1+ (Invitrogen) after PCR amplification using the primers 5 ¶-TATGGATCCGCAAGGGAGATCATGTTT-3 ¶ (sense) and 5 ¶-TATAAGCTTT-TATTGCACGAGTGGTGACTG-3 ¶ (antisense) containing restriction sites for BamHI and HindIII, respectively. Stable transfections in HME1 cells were carried out with Lipofectamine Plus (Invitrogen). Single stable clones were selected in puromycin 1 Ag/mL and four clones per each RNAi sequence were selected for further analysis.
Retroviral infection. Supernatants containing either the RARa dominant-negative LXRARa403SN or the empty LX SN (mock) retroviral particles (kindly provided by Dr. Fausto Andreola) were used to infect HME1 cells as described (21) . Four independent clones were used for further analysis.
Real-time reverse transcription-PCR. Total RNA obtained with the single-step method using Trizol (Invitrogen) was treated with DNase I (Ambion, Austin, TX). For each sample, 1 Ag total RNA was retrotranscribed with SuperScript First-Strand Synthesis System (Invitrogen) in a 20 AL reaction. One microliter of the so obtained cDNA was then used for each triplicate in real-time reverse transcription-PCR, which was done on an iCycler (Bio-Rad, Hercules, CA) using the iQ SYBR Green Supermix (BioRad) with primers specific for CRBP1 Western blot. Western blot analysis of RARh2, FLAG-CRBP1, and GAPDH protein expression was done with standard protocols using an antiRARh2 antibody (Santa Cruz Biotechnology, Santa Cruz, CA), an anti-FLAG M2 monoclonal antibody (Sigma) recognizing the TAG encoded by the CMV-TAG vector, and an anti-GAPDH antibody (Santa Cruz Biotechnology). Appropriate horseradish peroxidase-conjugated secondary antibodies (Amersham, Piscataway, NJ) were used for detection.
Quantitative chromatin immunoprecipitation. Chromatin immunoprecipitation (ChIP) was done using reagents purchased from Upstate (Lake Figure 1 . CRBP1 silencing does not induce RARb2 silencing and RA resistance. A, two sequences, CRBP1-A and CRBP1-B (top), cloned in the pSUPER-retro vector and able to efficiently abrogate the expression of exogenous CRBP1 in COS cells transfected with human CRBP1 cDNA (bottom ), were stably transfected into HME1 cells. B, two HME1 clones, Si-Crbp1-A1 carrying CRBP1-A and Si-Crbp1-B4 carrying CRBP1-B, showing significant (P < 0.001) CRBP1 transcriptional down-regulation compared with the control clone, mock-7, carrying a scrambled sequence (top, left ), displayed both anchorage-independent growth (top, right ) and an impaired epithelial polarization in three-dimensional culture [blue , nuclei; red, Golgi apparatus; green , integrin (bottom )]. C, Si-Crbp1-A1 and Si-Crbp1-B4 with unaffected RARb2 transcriptional activity (left ) are RA sensitive (right ). DNA methylation analysis. Genomic DNA was extracted with DNAzol (Invitrogen) and modified with sodium bisulfite as described previously (22) . We amplified by seminested PCR a 449-bp region of the CRBP1 CpG island encompassing 45 CpG sites using specific primer sets [5 ¶-AGGTTTT-AGATAAAGGTTTGTAAGTG-3 ¶ (sense-1), 5 ¶-GTGGTTGTTGAGTGTGA-GAAG-3 ¶ (sense-2), and 5 ¶-CACCAAACCACAACTCACCAAA-3 ¶ (antisense)] and a region encompassing a CpG stretch, which we defined as the RARb2 methylation epicenter (RME; ref. 8). To sequence single alleles, the PCR products were cloned into the pCR4-TOPO plasmid vector (Invitrogen).
In silico analysis of human CRBP1. To analyze the DNA region 5 ¶ to hCRBP1, the hCRBP1 transcript sequence from the Ensemble database (ENST00000232219) and the National Center for Biotechnology Information (NCBI) database (NM_002899.2) were compared with both the sequence encoding human DNA for CRBP1 and exons 1 and 2 (and joined coding sequence) from the NCBI database (X07437), and the complete sequence of the human 3 BAC RP11-553K23 clone (Roswell Park Cancer Institute Human Bacterial Artificial Chromosome Library, Buffalo, NY) deposited at the NCBI database (AC046134).
Statistical analysis. Statistical significance was calculated based on three independent experiments using the Student's t test.
Results
CRBP1 knockdown in HME1 cells does not lead to RARb2 silencing and RA resistance. CRBP1 is a protein critically involved in the transport and mobilization of retinol, the precursor of RA (23, 24) . Previously, we speculated that lack/derangement of proteins involved in retinol/RA metabolism could alter the intracellular concentration of RA, thus leading to RARb2 epigenetic silencing (8, 9) . The findings presented here discount that this might be the case for CRBP1. When we simulated the occurrence of CRBP1 epigenetic down-regulation in HME1 cells by knocking down CRBP1 transcription by RNAi with two sequences, CRBP1-A and CRBP1-B (Fig. 1A, top) , selected to efficiently silence an exogenously expressed human CRBP1 protein in COS cells (Fig. 1A,  bottom) , we did not induce RARb2 silencing, and consistently, we did not observe the conversion to RA resistance (Fig. 1C) . Four independent HME1 clones, two per each sequence, showing significant CRBP1 transcriptional down-regulation relative to a prototypic control clone, mock-7, carrying a scrambled sequence, were analyzed. Here, we show that for two representative clones, Si-Crbp1-A1 and Si-Crbp1-B4, which were stably transfected with the sequences CRBP1-A and CRBP1-B, respectively (Fig. 1B, top,  left ) , the induction of CRBP1 knockdown confers the two phenotypes expected for CRBP1 down-regulation (14, 25) , including anchorage-independent growth in soft agar (Fig. 1B, top, right) and impaired apicobasal polarization when grown on basement membrane in three-dimensional cultures. Both clones formed mainly acini with a filled lumen (Fig. 1B, bottom) ; however, they maintained a transcriptionally active RARb2 (Fig. 1C, left) and remained sensitive to the growth-inhibitory action of RA (Fig. 1C, right) .
Evidence that hCRBP1 is a direct RAR target, epigenetically regulated in response to RA. Previous reports implied that CRBP1 might be a direct RAR target gene (15) (16) (17) (18) (19) . We located by in silico analysis (see Materials and Methods) a human CRBP1-RARE 1,377 bp upstream of the hCRBP1 transcription start site ( Fig. 2A) , which is highly homologous to both mouse and rat CRBP1-RARE sequences (15, 16) . Second, we found that RA (1 AM, 72 hours) activated both RARb2 and CRBP1 transcription in HME1 cells (Fig. 2B, top) in association with a significant increase of histone H4 acetylation at both the RARb2-RARE and the CRBP1-RARE chromatin regions (Fig. 2B, middle) , which is consistent with the scanty DNA methylation in just a minority of HME1 alleles (Fig. 2B, bottom) . Conversely, both RARb2 and CRBP1 in MDA-MB-231 cells were transcriptionally silent (Fig. 2C, top) , hypoacetylated at histone H4 (Fig. 2C, middle) , and showed DNA hypermethylation (Fig. 2C, bottom) . The transcription of both genes was concomitantly reactivated by RA (1 AM) after partial reversion of the DNA hypermethylated status by 5-Aza (0.8 AM, 72 hours; Fig. 2C, top) . Altogether, these data implied that the transcription of both RARb2 and CRBP1 is epigenetically regulated in a concerted fashion in response to RA. This supposition was reinforced by ChIP analysis with anti-RARh2-specific antibodies, which detected RARh2 binding at the CRBP1-RARE but not at an adjacent 5 ¶ control region (Fig. 2D, left ). In addition, the level of RARh2 binding increased in response to RA, concomitant with a decrease of RARa binding at the CRBP1-RARE (Fig. 2D, right) . These data prompted us to test whether CRBP1 transcription is under direct RAR regulation.
RARb2 knockdown in HME1 cells leads to CRBP1 epigenetic silencing. When we down-regulated RARb2 transcription in HME1 by RNAi, we observed down-regulation of CRBP1 transcription, which remained unresponsive to RA. We used two sequences, RARh2-A and RARh2-B (Fig. 3A, top) , which efficiently silenced RARh2 RARh2 expression from an exogenous RARb2 cDNA transfected in COS cells (Fig. 3A, bottom) , to stably transfect HME1 cells. Four independent clones, two per each sequence, showing significant RARb2 transcriptional down-regulation and RA resistance (Fig. 3B , top, left and right, respectively) yet unaffected levels of RARa transcription (Fig. 3B, bottom) relative to a representative control clone, mock-8, were selected for further analysis. The clones tested included Si-h-A8, carrying the RARh2-A sequence, and Si-h-B4, carrying the RARh2-B sequence (Fig. 3B, left) . In both Si-h-A8 and Si-h-B4 CRBP1 alleles were clearly nonpermissive for transcription Figure 3 . RARb2 knockdown in HME1 cells leads to CRBP1 epigenetic silencing. A, the RARh2-A and RARh2-B sequences (top ) efficiently silenced exogenous RARh2 expression in COS cells cotransfected with human RARh2 cDNA (bottom ). B, two HME1 clones, Si-h-A8 carrying RARh2-A and Si-h-B4 carrying RARh2-B, showing specific and significant down-regulation of RARb2 (P < 0.01; top, left) but not of RARa (bottom ) acquired RA resistance (top, right ) compared with the control clone mock-8, carrying a scrambled sequence. C, both Si-h-A8 and Si-h-B4 show significant (P < 0.001) CRBP1 transcriptional down-regulation. D, distribution of CpG methylated sites (top ) in de novo methylated, nonpermissive alleles of the Si-h-A8 clone (bottom ). E, Si-h-A8 and Si-h-B4 clones showing anchorage-independent growth (left ) and impaired epithelial cell differentiation in three-dimensional cultures (right ). (Fig. 3C) . A fraction of the alleles nonpermissive for transcription (shown here are the alleles of the Si-h-A8 clone) acquired de novo DNA methylation over the CRBP1 CpG island (Fig. 3D, top and  bottom) .
Epigenetic Domino Effects in Breast Tumorigenesis
Both Si-h-A8 and Si-h-B4 failed to form polarized, hollow lumen acini when grown on reconstituted basement membrane (threedimensional cultures; Fig. 3E, right) , and both displayed anchorage-independent growth (Fig. 3E, left ) . Apparently, RARb2 transcriptional repression leads to both CRBP1 epigenetic repression and associated morphologic phenotypes. These data led us to test whether an impaired RA signal at RARa can trigger a repressive epigenetic ''domino effect'' involving both RARb2 and its target CRBP1.
An impaired RA signal at RARA leads to concomitant RARb2 and CRBP1 epigenetic repression. Interference with either RARa transcription by RARa RNAi or RARa function with a dominant-negative RARa mutant (RARa403; ref. 21 ) in HME1 cells confirmed that indeed this was the case. Both the RARa knockdown clone Si-a-1, carrying the RARa-B silencing sequence (Fig. 4A, top, left; ref. 8) , and the DN a4 clone, carrying the dominant-negative RARa403 mutant (Fig. 4A, top, right) , displayed stable repression of endogenous RARb2 and CRBP1 transcription relative to the respective control clones, mock-1, carrying a scrambled sequence, and LX C3, carrying an empty vector (Fig. 4A, middle and bottom) . The chromatin of both genes underwent histone H4 hypoacetylation. We conclude that this is the case because RA did not raise significantly histone H4 acetylation (Fig. 4B, left and right) . In addition, we observed de novo DNA methylation in the RME (8) and CRBP1 CpG island (Fig. 4C , top and bottom) in clones impaired for RARa, but not in the mock controls.
The phenotypes acquired by both Si-a-1 and DN a4 clones fully recapitulated the phenotypes observed after RARb2 and CRBP1 silencing, including resistance to RA, anchorage-independent growth, and aberrant epithelial polarization when cells were grown as acini in three-dimensional cultures (Fig. 4D) . Interestingly, these phenotypes were described previously in a human mammary epithelial cell strain transfected with the RARa403 mutant (26, 27) .
We conclude that an impaired RA signal through RARa can cause a coordinated, epigenetic repression of RARb2 and its direct target CRBP1.
Discussion
In this study, we show that an interference with RA signal at RARa in RA-sensitive, untransformed, human mammary epithelial cells converts in a coordinated succession two RA-responsive genes, RARb2 and its direct target CRBP1, into a status nonpermissive for transcription. Interestingly, a fraction of nonpermissive RARb2 and CRBP1 alleles acquires also chromatin repressive modifications, including de novo DNA methylation. This is the first Figure 4 . Functional inhibition of RARa induces concomitant CRBP1 and RARb2 epigenetic silencing. A, HME1 stable clones, such as the prototypical Si-a-1, carrying the RARa-B RNAi sequence (top, left ), or the prototypical DN a4, carrying the dominant-negative construct RARa403 (top, right ), showing significant (P < 0.01) down-regulation of both RARb2 (middle ) and CRBP1 (bottom ) transcription compared with the cognate control clones. B, Si-a-1 clone showing significant histone H4 hypoacetylation in response to RA (P < 0.05) at both RARh2-RARE and CRBP1-RARE. C, left, distribution of CpG methylated sites in 10 RARb2 (top ) and 10 CRBP1 (bottom ) nonpermissive hypermethylated alleles, respectively, out of the nonpermissive alleles of S1-a-1 shown in the pie graphs (right ). D, evidence of RA resistance (top, left ), anchorage-independent growth (top, right ), and impaired epithelial polarization in three-dimensional cultures (bottom) in both Si-a-1 and DN a4 clones.
evidence of a repressive epigenetic domino effect involving two RA-responsive genes consequent to an impaired RA signal. As a consequence of this epigenetic domino effect, human breast epithelial cells acquire in a succession RA resistance and distinct phenotypes of breast epithelial transformation, such as loss of epithelial polarization, inability to form a hollow lumen in threedimensional basement membrane cultures, and anchorage-independent growth.
Recently, we showed that an impaired RA signal through RARa in RA-sensitive, transformed breast cancer cells leads to RARb2 epigenetic silencing (8) . Apparently, an interference with RA signal through RARa would trigger the silencing of genes that are normally epigenetically regulated by RA. Further, transcriptional silencing is clearly marked by aberrant repressive chromatin changes not only in transformed but also in untransformed cells. We do not know yet by which mechanism the transcriptionally inactive status created by lack of integration of RA signal through RARa can invoke repressive modifying enzymes capable of imposing both histone and DNA repressive changes at RAR-regulated genes. We are tempted to speculate that, as it happens during the heterochromatinization of the transcriptionally inactive chromosome X (28, 29) , an RNAmediated mechanism may play a role in the heterochromatinization of transcriptionally inactive autosomal gene regions. Apparently, only a fraction of nonpermissive RARb2 or CRBP1 alleles develops aberrant de novo DNA methylation, which would indicate that it is the nonpermissive status that recalls DNA methylation and not the other way around. As for chromosome X, DNA methylation would ''lock in'' the silent status of nonpermissive alleles.
Interestingly, here we show that RARa, via RARb2, controls the transcription of CRBP1, a gene involved both in retinol transport and breast epithelial cell morphogenesis. We found recently that RARa, via RARb2, controls the transcription of another RAresponsive gene, CYP26A1, an enzyme implicated in RA catabolism and neural morphogenesis (ref. 30 and references within). Thus, RA-RARa signal seems to control, through a concerted epigenetic mechanism, at least two RA-responsive genes involved in retinol/ RA metabolism as well as morphogenesis. The gradient of retinoids is critical for symmetry and morphogenesis during organismal development (31) (32) (33) . This could also be true during postnatal development of the mammary gland. The results shown here lend support to the hypothesis that retinoid metabolism is intertwined with retinoid-dependent morphogenesis. Specifically, RA itself would epigenetically regulate through its own metabolism critical morphogenetic programs.
Our study also provides useful information for improving a breast cancer prediction test, thus far based on RARb2 hypermethylation analysis alone (34) . In light of what we showed here, RARb2 hypermethylation cannot distinguish between cells heterozygous for RARb2 nonpermissive alleles, thus still sensitive to RA, from cells homozygous for RARb2 nonpermissive alleles, thus RA resistant. Only the latter would have tumor phenotypic features. Combining RARb2 and CRBP1 epigenetic analysis might provide a better test for predicting breast cancer susceptibility.
